New Structural Biology Lab Slated for San Diego

San Diego will be adding to its dynamic and growing life sciences base. Privately-held Structural GenomiX, Inc. (SGX) today announced the formation of a research and technology collaboration with Eli Lilly and Company (LLY). Within the research collaboration, SGX will apply its proprietary gene-to-structure technology to key Lilly drug targets to determine their 3-dimensional structures.

Structural GenomiX, Inc. (SGX) is a structure guided drug discovery company accelerating the discovery of novel therapeutics to treat human diseases. SGX technologies include advanced bioinformatics, automated molecular biology and protein engineering, high-throughput crystallization, streamlined structure determination, high-throughput compound docking and medicinal chemistry. SGX technology drives the lead optimization process through iterative determination of co-crystal structures that reveal, in atomic detail, how small molecules interact with drug targets.

SGX has established unparalleled capacity in this area by building a world-class facility for the collection of macromolecular X-ray diffraction data at the Advanced Photon Source (APS), located at the U.S. Department of Energy's Argonne National Laboratory. SGX has multiple internal drug discovery programs focusing in the therapeutic areas of oncology and inflammation. The company is based in San Diego, California. For more information, please visit the company's website at www.stromix.com.